Free Trial
→ Do NOT Buy SpaceX – Do This Instead (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
$0.43
$0.44
$0.15
▼
$0.97
$1.42M-0.236,726 shs329 shs
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
$1.41
+2.9%		$1.51
$1.16
▼
$5.24
$5.15M1.9340,080 shs22,088 shs
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$1.15
-0.9%		$1.29
$0.85
▼
$4.25
$5.51M1.3120,115 shs31,299 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
+2.38%-4.23%-36.91%+72.00%-48.98%
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
-0.72%-8.05%-5.78%-14.91%-72.04%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-1.69%-4.92%-10.08%-4.92%-71.50%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
$0.43
$0.44
$0.15
▼
$0.97
$1.42M-0.236,726 shs329 shs
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
$1.41
+2.9%		$1.51
$1.16
▼
$5.24
$5.15M1.9340,080 shs22,088 shs
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$1.15
-0.9%		$1.29
$0.85
▼
$4.25
$5.51M1.3120,115 shs31,299 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
+2.38%-4.23%-36.91%+72.00%-48.98%
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
-0.72%-8.05%-5.78%-14.91%-72.04%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-1.69%-4.92%-10.08%-4.92%-71.50%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
0.00
N/AN/AN/A
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
1.00
SellN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest ATXI, SNOA, and PULM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/21/2026
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D-) ➝ Sell (E+)
8/14/2026
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D-) ➝ Sell (E+)
8/7/2026
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E+) ➝ Sell (D-)
7/30/2026
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E+) ➝ Sell (D-)
7/24/2026
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
7/15/2026
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/AN/AN/AN/A$1.92 per shareN/A
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
N/AN/AN/AN/A$2.45 per shareN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$19.53M0.28N/AN/A$0.65 per share1.77
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
-$10.38M-$0.850.02N/AN/AN/A-471.57%-296.50%11/13/2026 (Estimated)
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
-$5.16M-$1.10N/AN/AN/AN/A-125.65%-95.19%11/5/2026 (Estimated)
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$3.17M-$1.22N/AN/AN/A-10.33%-21.41%-6.08%11/16/2026 (Estimated)

Latest ATXI, SNOA, and PULM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
-$2.00N/AN/AN/A$1.53 millionN/A
8/13/2026Q2 2026
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
-$2.00-$0.29+$1.71-$0.29N/AN/A
8/6/2026Q1 2027
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$0.30$0.02+$0.32-$0.09$4.99 million$6.41 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/AN/AN/AN/AN/A
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
N/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/A
2.70
2.70
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
N/A
4.70
4.70
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/A
2.99
2.29

Institutional Ownership

CompanyInstitutional Ownership
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
17.34%
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
11.84%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.95%

Insider Ownership

CompanyInsider Ownership
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
8.60%
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
0.62%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.02%
CompanyEmployeesShares OutstandingFree FloatOptionable
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
43.30 million2.02 millionNot Optionable
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
23.65 million3.63 millionNot Optionable
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
2604.79 million4.74 millionNot Optionable

Recent News About These Companies

Sonoma Pharmaceuticals Cancels Adjourned Special Stockholder Meeting
August 19, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/sonoma-pharmaceuticals-cancels-adjourned-special-stockholder-meeting?utm_source=marketbeat.com&utm_medium=referral
Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA
August 6, 2026  |  accessnewswire.comA
Sonoma Pharmaceuticals Turns EBITDA Positive for First Time with Record Quarterly Revenue
August 6, 2026  |  benzinga.comhttps://www.benzinga.com/markets/earnings/26/08/60993290/sonoma-pharmaceuticals-turns-ebitda-positive-for-first-time-with-record-quarterly-revenue?utm_source=snapi
Sonoma Pharmaceuticals Receives FDA 510(k) Clearance Expanding Indications and Packaging Options for Microdacyn(R) Wound Irrigation Solution
June 30, 2026  |  accessnewswire.comA
Sonoma Pharmaceuticals Expands At-the-Market Equity Offering Capacity
June 18, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/sonoma-pharmaceuticals-expands-at-the-market-equity-offering-capacity?utm_source=marketbeat.com&utm_medium=referral
Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial Results
June 16, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-06/68784561-sonoma-pharmaceuticals-inc-sonoma-pharmaceuticals-reports-fiscal-year-and-fourth-quarter-2026-financial-results-200.htm
Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial Results
June 16, 2026  |  accessnewswire.comA
What's going on with Sonoma Pharma stock Monday?
April 27, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/what-s-going-on-with-sonoma-pharma-stock-monday/ar-AA21PdPx
Sonoma Pharmaceuticals Announces Pricing of $4 Million Public Offering
April 25, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/sonoma-pharmaceuticals-announces-pricing-4-132100121.html
Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Announces U.S. Retail Launch of Advanced Burn Relief Hydrogel in CVS and Walmart
March 24, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-03/68022819-sonoma-pharmaceuticals-inc-sonoma-pharmaceuticals-announces-u-s-retail-launch-of-advanced-burn-relief-hydrogel-in-cvs-and-walmart-200.htm
Sonoma Pharmaceuticals Announces U.S. Retail Launch of Advanced Burn Relief Hydrogel in CVS and Walmart
March 24, 2026  |  accessnewswire.comA
Sonoma Pharmaceuticals Announces Launch of New Dermatology Product Line under Person & Covey’s Aquanil Brand for Sensitive Skin
March 18, 2026  |  freep.comF
Sonoma Pharmaceuticals Announces Launch of New Dermatology Product Line under Person & Covey's Aquanil Brand for Sensitive Skin
March 18, 2026  |  accessnewswire.comA
Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2026 Financial Results
February 10, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-02/67666437-sonoma-pharmaceuticals-inc-sonoma-pharmaceuticals-reports-third-fiscal-quarter-2026-financial-results-200.htm
Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2026 Financial Results
February 10, 2026  |  accessnewswire.comA
Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development
January 29, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-01/67552599-sonoma-pharmaceuticals-inc-sonoma-pharmaceuticals-welcomes-new-member-of-its-board-of-directors-and-new-senior-vice-president-of-regulatory-qualit-200.htm
Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development
January 28, 2026  |  accessnewswire.comA
Sonoma Pharmaceuticals, Inc.: National Rosacea Society Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced
November 14, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-11/66971748-sonoma-pharmaceuticals-inc-national-rosacea-society-awards-seal-of-acceptance-to-sonoma-pharmaceuticals-for-reliefacyn-advanced-200.htm
Sonoma Pharmaceuticals’ Reliefacyn Advanced receives NRS Seal of Acceptance
November 13, 2025  |  msn.comhttps://www.msn.com/en-us/health/diseases-and-conditions/sonoma-pharmaceuticals-reliefacyn-advanced-receives-nrs-seal-of-acceptance/ar-AA1QnZQ4
National Rosacea Society Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced
November 13, 2025  |  accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Avenue Therapeutics stock logo

Avenue Therapeutics NASDAQ:ATXI

$0.43 0.00 (0.00%)
As of 10/14/2026 12:02 PM Eastern

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.

Pulmatrix stock logo

Pulmatrix NASDAQ:PULM

$1.41 +0.04 (+2.92%)
Closing price 03:58 PM Eastern
Extended Trading
$1.48 +0.08 (+5.32%)
As of 06:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.

Sonoma Pharmaceuticals stock logo

Sonoma Pharmaceuticals NASDAQ:SNOA

$1.15 -0.01 (-0.86%)
Closing price 03:59 PM Eastern
Extended Trading
$1.16 +0.01 (+0.43%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas